06996.HK
Antengene Corporation Limited
HKSE · Healthcare · Biotechnology · CN
HKD 3.56
−0.70%Year over year
Reported trailing growth
- Revenue
- +174.3%
- EBITDA
- +93.4%
- EBIT
- +91.2%
- EPS
- +85.7%
- Free cash flow
- +86.8%
- Operating cash flow
- +88.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.0%
- EBITDA
- +36.6%
- EBIT
- +34.5%
- Net income
- +25.1%
- EPS
- +25.5%
- Free cash flow
- +53.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026